Pro prostate specific antigen: A new marker for prostate cancer;Le pro PSA : Un nouveau marqueur du cancer de la prostate

Progres en Urologie

Volumn 14, Issue SPEC. ISS. SEPT., 2004, Pages 8-11

  Peyromaure, Michaël ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN SPECIFICITY; BIOCHEMISTRY; EPITHELIUM CELL; HUMAN; PROSTATE CARCINOMA; REVIEW;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 8144228125     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 21: 383-391, 2003.
2. Mikolajczyk SD, Grauer LS, Millar LS, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50: 710-714, 1997.
3. Peter J, Unverzagt C, Krogh TN, et al. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61: 957-962, 2001.
4. Mikolajczyk SD, Rittenhouse HG. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 52: 86-91, 2003.
5. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: 1542-1547, 1998.
6. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277: 1452-1455, 1997.
7. Mikolajczyk SD, Millar LS, Wang TJ, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60: 756-759, 2000.
8. Mikolajczyk SD, Marker KM, Millar LS, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61: 6958-6963, 2001.
9. Sokoll LJ, Chan DW, Mikolajczyk SD, et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology 61: 274-276, 2003.
10. Khan MA, Partin AW, Rittenhouse HG, et al. Evaluation of prosprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 170: 723-726, 2003.
11. Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170(6 Pt 1): 2181-2185, 2003.
12. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565, 2001.